Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its quarterly earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.09, Zacks reports. The firm had revenue of $26.90 million for the quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.79 on Friday. The stock has a market capitalization of $127.56 million, a P/E ratio of -0.72 and a beta of 1.75. Zentalis Pharmaceuticals has a fifty-two week low of $1.61 and a fifty-two week high of $16.27. The company has a 50 day moving average price of $2.05 and a 200 day moving average price of $2.86.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was acquired at an average cost of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jan Skvarka bought 60,000 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZNTL shares. UBS Group reduced their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Wedbush reissued a “neutral” rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday. Finally, Wells Fargo & Company dropped their price target on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.